

---

THE ONE CLICK GROUP  
www.theoneclickgroup.co.uk  
Email: mail@theoneclickgroup.co.uk

## **THE PACE REPORT**

### **THE MRC / PACE TRIAL SCANDAL**

Should patients boycott this trial? We call for a Public Inquiry

**Prepared by:**

**Jane Bryant**

**April 2004**

**THE ONE CLICK GROUP**

<http://www.theoneclickgroup.co.uk/>

# THE PACE REPORT

<b>CONTENTS</b>	<b>PAGE</b>
THE PACE (PACING, ACTIVITY AND COGNITIVE BEHAVIOUR THERAPY: A RANDOMISED EVALUATION) TRIAL	3
THE OXFORD CRITERIA	4
THE ACTION FOR ME (AfME) INVOLVEMENT	5
THE CANADIAN DEFINITION OF ME/CFS	6
THE PACE TRIAL IDENTIFIER	8
CONCLUSION	9
THE PACE TRIAL IDENTIFIER – THE MEDICAL RESEARCH COUNCIL	10
1. Trial Identifier	10
2. The need for a trial	10
3. The proposed trial	12
4. Trial management	19
5 Financial details of the trial	20
6 Application History	22
Appendices	22

# **THE PACE REPORT**

## **THE MRC / PACE TRIAL SCANDAL**

Should patients boycott this trial? We call for a Public Inquiry

By Jane Bryant, April 2004

### **THE PACE (PACING, ACTIVITY AND COGNITIVE BEHAVIOUR THERAPY: A RANDOMISED EVALUATION) TRIAL**

One of the worst scandals in UK medical history is set to erupt shortly over a psychiatric clinical trial that has been approved and funded by the Medical Research Council (MRC) ostensibly to benefit sufferers from the neurological disease ME/CFS ICD-10 G93.3. According to one of the trial leaders, about £4m of British taxpayers money is scheduled to be wasted in the conduction of these trials that in the case of the PACE trial, specifically excludes the very patient group that it is supposed to be studying.

In February of this year the Health Minister, Lord Warner, confirmed that the UK accepts that ME/CFS is a neurological disease and listed as such by the World Health Organisation (WHO) under ICD-10 G93.3. And yet the PACE trial will study only psychosocial management regimes and treatments that have been comprehensively shown to be at best ineffective and in many instances have made sufferers of ME/CFS considerably worse. The MRC is very well aware of this fact.

Led by a group of psychiatrists and designed by Professor Simon Wessely who will oversee the Clinical Trial Unit, the PACE trial is to study and compare the psychosocial management/treatment regimes of Adaptive Pacing Therapy (APT), Cognitive Behavioural Therapy (CBT) and Graded Exercise Therapy (GET) for the sufferers of ME/CFS. Professor Simon Wessely who will direct the randomisation, data base design and management of the trial is notorious worldwide for his on the record and published views that ME is simply an erroneous belief system and not the neurological disease that it is recognised to be by international consensus and the WHO, listed under ICD-10 G93.3.

The doctors carrying out the research are, themselves, employed to provide the therapies being studied. As such, they have a monetary vested interest in showing that they are effective. This must surely explain why such 'inclusive' criteria were used since people with other types of chronic fatigue who are NOT ME/CFS SUFFERERS, (CFS being the supposed subject of the study), may well find these therapies helpful.

Pacing as used by the ME/CFS sufferers right around the globe in no way resembles Adaptive Pacing Therapy (APT). Pacing as used by ME/CFS sufferers aims at a sustainable lifestyle involving the careful management of energy output so as to promote stabilisation and healing, thus reducing relapses and minimising symptoms. Pacing does not feature targets and goals other than this. Pacing as used by ME/CFS sufferers is diametrically different from APT that sets targets and goals and for which there is no apparent and credible scientific support.

These psychosocial treatments are to be trialled at the newly operational ME/CFS centres recently announced by the Department of Health, UK. The combination funding for the new ME/CFS centres and the trials amounts to some £11.1m that is currently being ring fenced and devoted to psychosocial treatments for an organic illness; treatments that have not only failed at best to benefit sufferers in the past, but have also actively damaged many.

## THE OXFORD CRITERIA

In May 2003, the MRC announced that the Oxford criteria are to be used as the criteria for the PACE trial. Produced by a group of UK psychiatrists in 1991, the Oxford criteria have been superseded, are outdated, have no predictive value and are not in use by international consensus.

See full text of the Oxford criteria here:

[http://www.theoneclickgroup.co.uk/documents/ME-CFS\\_res/CFS%20Oxford%20Criteria%201991.pdf](http://www.theoneclickgroup.co.uk/documents/ME-CFS_res/CFS%20Oxford%20Criteria%201991.pdf)

The Oxford Criteria specifically **exclude** patients suffering from a neurological disorder and therefore by definition all 240,000 sufferers of the neurological disease ME/CFS – 40,000 of them children in the UK. Moreover, patients suffering from the disease Fibromyalgia are to be included in the PACE trial. Fibromyalgia is classified in the WHO ICD at M79 as a distinct entity. Fibromyalgia is a quite separate disorder from ME/CFS, with a discrete biomedical profile that is entirely distinct from that found in ME/CFS. There is absolutely no scientific rationale for including Fibromyalgia patients in the PACE trial.

The Oxford criteria are so wide that anyone suffering from fatigue for six months or more could be included in the PACE trial. On this basis it is quite clear that the Oxford criteria have been selected so as to **enhance the numbers recruited** and include the masses suffering from idiopathic chronic fatigue that is classified by the WHO under F48 as a mental disorder and totally separate to the neurological disease ME/CFS ICD- 10 G93.3.

The One Click Group asked the MRC as to who judged the use of the Oxford criteria to be appropriate for use in this trial? The MRC answered: “The independent experts from UK and abroad who peer reviewed the trial protocol considered the INCLUSION criteria to be appropriate for meeting the objective of the trial.”

When further questioned by The One Click Group as to how many of the so-called international ‘independent’ experts who peer reviewed the trial protocol were psychiatrists, how many were neurologists, neuropsychiatrists or psychologists, answer came there none.

It is scientifically dishonest for the MRC to accept, approve and fund a trial when the evidence clearly shows that is flawed from the outset by virtue of the fact that it cannot be including ME/CFS sufferers and yet claims to be doing so.

These ‘trials’ are quite clearly little more than job providers for certain psychiatrists, their helpers and supporters who operate on the basis of a misguided but entrenched illness belief that ME/CFS is a mental disorder, not the neurological illness that it is,

as recognised by the WHO, by the UK government and by international consensus worldwide.

**This is deceit and a scandal of massive proportions. How did it come about that £4m of British taxpayers money was agreed by the MRC to be spent on a trial that excluded the very patient population that it claims to be studying?**

### **THE ACTION FOR ME (AfME) INVOLVEMENT**

The charity AfME has been closely involved in the development of the PACE trial protocol and is being given government monies under Section 64 to represent the so-called 'best interests' of ME/CFS patients that transpire to be nothing of the kind.

This charity also has one of its key employees seconded to the Department of Health Secretariat and acting as Observer on the Steering Committee. AfME is currently under investigation because the policy, stance, direction and workings of this charity are not supported by its subscribers and the wider ME/CFS community. AfME has not seen fit to hold an Annual General Meeting that involved its subscribers since 1996.

**See the full text of THE AfME DOSSIER 2004 here:**

[http://www.theoneclickgroup.co.uk/documents/ME-CFS\\_char/AFME/THE%20AFME%20DOSSIER.pdf](http://www.theoneclickgroup.co.uk/documents/ME-CFS_char/AFME/THE%20AFME%20DOSSIER.pdf)

When Mr. Clark, the CEO of AfME, was very recently questioned over the psychosocial treatments on offer in the new ME/CFS centres, he maintained that 90% of ME/CFS sufferers found Pacing to be helpful. This is entirely correct. However, the fact of the matter is that the APT treatment in no way resembles Pacing and this Mr. Clark knows full well. Mr. Clark also stated that 50% of ME/CFS sufferers were helped by CBT/GET. This is demonstrably not the case.

In March 2001, AfME itself carried out a survey of 2,338 respondents entitled "Severely Neglected – M.E in the UK" that clearly stated "**graded exercise was reported to be the treatment that had made most people worse.**"

Quite how Mr. Clark manages to rationalise his charity's stance over the PACE trial for which AfME has obtained funds by government grant with the results of AfME's own survey, is a matter of intense speculation both in the UK and abroad.

In response to massive disquiet by the ME/CFS community over the use of the superseded and outdated Oxford criteria to be used for the PACE trial as announced by the MRC that by definition excludes all sufferers of ME/CFS, Mr. Chris Clark, the CEO of AfME, issued a statement on the 10<sup>th</sup> February 2004 and said that the Fukuda criteria would also be used for the PACE trial.

**See the AfME PACE trial statement here:**

<http://www.theoneclickgroup.co.uk/documents/PACE/PACE%20-%20AfME%20STATEMENT.txt>

When the MRC was questioned by The One Click Group as to the validity of announcing a separate set of criteria to be used **after** the PACE trial proposal had been already approved, a spokesperson for the MRC responded: "The AFME statement is correct. Patients will be entered into the trial using the Oxford criteria but

will then be further assessed against the other criteria (Fukuda and London) for secondary analysis.”

Secondary analysis? That’s rich. The MRC went on to say: “Applying the Fukuda and London criteria to the patients recruited under the Oxford criteria will enable finding out about sub groups of people including those who meet the WHO ICD-10 G93 classification.” Since **all** patients suffering from ME/CFS have **already been excluded from the PACE trial by definition of the use of the Oxford criteria, how can they be then analyzed a second time when they have not been included in the first place?** The foregoing statement by the MRC defies credibility.

The One Click Group also asked the MRC to list by name the number of trials that had been rigorously scrutinised and approved using one set of criteria and then other additional bolt on sets of criteria subsequently added. The MRC refused to provide any details despite repeated request.

### **THE CANADIAN DEFINITION OF ME/CFS**

Produced by an Expert Medical Consensus Panel of eleven physicians who have between them treated/diagnosed over 20,000 ME/CFS sufferers worldwide, the Canadian Definition of ME/CFS, Diagnostic and Treatment Protocols sets out the most recent and carefully compiled criteria and seeks to rectify problems encountered in many studies so far. Published in 2003, these criteria most closely define those ME/CFS patients who not only suffer from bone crushing fatigue, but also from a wide range of neurological, immunological, and endocrinological problems, i.e. those who would come under the WHO classification of ME/CFS ICD-10 G93.3. It is these Canadian criteria that have international consensus that should be used for the PACE trial and any other clinical trial in relation to ME/CFS.

**See the full text of the Canadian Definition of ME/CFS here:**

[http://www.theoneclickgroup.co.uk/documents/ME-CFS\\_docs/Canadian%20Definition%20of%20ME-CFS.pdf](http://www.theoneclickgroup.co.uk/documents/ME-CFS_docs/Canadian%20Definition%20of%20ME-CFS.pdf)

Other charities that work in the ME/CFS field such as the Myalgic Encephalopathy Association (MEA – currently under investigation), the Association of Young ME sufferers (AYME) and unsurprisingly AfME – also under investigation and who has an entire conflict of interest over this issue - have refused to even pass comment on Canadian criteria that represent the international consensus breakthrough for ME/CFS sufferers worldwide.

When the MRC was questioned by The One Click Group as to precisely why the Canadian criteria were not to be used for the PACE trial, the MRC spokesperson said: “There is no international consensus. International reviewers were involved in reviewing PACE along with those in the UK and they were satisfied the **INCLUSION** criteria was appropriate for meeting the objective of the trial.”

From its own mouth, the MRC damns itself. The Oxford criteria are being used so as to **INCLUDE** patients who will most likely respond to the treatments and **EXCLUDE** those who will not – specifically sufferers of the neurological disease ME/CFS ICD-10 G93.3.

These ME/CFS clinics are supposed to be treating patients - not recruiting people for research. The money that they are being set up with is money for SERVICES - NOT RESEARCH. And since this is the case, what is the point in the clinics using anything OTHER than clinical diagnostic criteria - except of course to provide guinea pigs for research?

This study is clearly set up to provide jobs and prestige for the 'boys'.

## **THE PACE TRIAL IDENTIFIER**

Amidst this huge outcry by the ME/CFS community and the controversy of what it is being said could well amount to scientific misconduct and fraud in regard to the PACE trial, The One Click Group was given a copy of the PACE Trial Identifier. The full contents of this document are published below.

**The PACE Trial Identifier is also available online here:**

<http://www.theoneclickgroup.co.uk/documents/PACE/THE%20PACE%20TRIAL%20IDENTIFIER%20.pdf>

This is the document that the MRC did not want you to see. It did not want you to see it because it contains the chapter and verse protocols and costs of the PACE trial and highlights so clearly the brain washing exercise that is being carried out over this trial par excellence at taxpayers expense. This PACE Trial Identifier is an insult to all severely, physically ill patients of the neurological disease ME/CFS. This trial will do nothing to enhance the understanding of this disease or help patients in any lasting and fundamental way.

You will see that the PACE trial is to be designed and managed by Professor Simon Wessely; that Dr. Peter White, Michael Sharpe and Trudie Chalder will be centre leaders. Also involved will be Professor Anthony Pinching, Dr. David Wilks, Professor Tim Peto, Dr. Eleanor Feldman, Dr. Gabrielle Murphy, Dr. Tony Johnson, Professor Janet Derbyshire, Professor Tom Meade, Professor Martin Knapp, Ms. Diane Cox, Mr. Vincent Deary, Dr. Paul McCrone, Dr Meirion Llewelyn, Professor Anne Farmer, Professor Tom Craig, Mrs. Frankie Campling (ex-sufferer and CFS counsellor). And last but by no means least, we have our very own Mr. Chris Clark from AfME as part of the Management Committee.

Amongst the many nuggets in the PACE Trial Identifier it is stated that: **“COMPLIANCE with both the treatments and the study will be maximized by the COLLABORATION and SUPPORT of AfME..... in the trial.”** AfME compliance, collaboration and support in relation to the psychosocial PACE trial? This sentence is reminiscent of how collaborators behaved during the Second World War! AfME has obtained government monies to recruit and attempt to obtain the compliance of ME/CFS sufferers in relation to this trial that by Oxford criteria definition precludes them from entry!

The document also states that previously found predictors of a negative outcome with treatment include membership of a self-help group and being in receipt of a disability pension.

It is quite clearly the case that they wish to **investigate the role of Benefits as a predictor of poor outcome.** It will then be found of course that if the Benefits are

provided, the person has a poor outcome. Ergo, if the Benefits are not given, the person will have to work for a living.

Subjects will be discouraged from starting over the counter medicines or alternative treatments. This is particularly poignant since it has been shown that it is precisely these treatments that can assist some ME/CFS sufferers the most, even though there is no cure.

As is always the case, those most severely afflicted by ME/CFS will not be studied because they are too ill to be able to attend these ME/CFS centres

### **Some Fundamental Questions That Require Urgent Answer**

1. What gives this group of psychiatrists and their supporters the right to impose inappropriate coping/management regimes on severely ill patients, despite the fact that such methods have been shown to either make little or no difference or in many cases worsen the illness, sometimes dramatically?
2. What was the purpose of setting up the Chief Medical Officer's Working Group, preparing a complex report, taking into account at least some of the patients' views and then to all intent and purposes, ignoring them completely? And this despite the 'Expert Patient' initiatives currently being touted by the UK Government?
3. Why are the Canadian criteria not being adopted for all ME/CFS clinical trials?
4. Why are the UK ME/CFS charities – and especially their principal representatives – not representing their members properly?
5. Why is £4m of taxpayer's money being wasted on this PACE trial that by definition and design excludes ME/CFS sufferers – the very group of patients that is supposed to be studied?
6. Why are no funds being directed to research of the aetiology of biomedical aspects of ME/CFS?
7. Is it ethical for people with proven commercial interests in these studies to be designing and running these trials, given the proven evidence of their personal commercial interests in the desired outcome of these trials?

**This PACE Trial Identifier (see below) should be as widely distributed as possible.**

Jane Bryant

**THE ONE CLICK GROUP**

<http://www.theoneclickgroup.co.uk/>

April 2004

---

**This document is available online at:**

<http://www.theoneclickgroup.co.uk/documents/PACE/THE%20PACE%20TRIAL%20IDENTIFIER%20.pdf>

## **THE PACE TRIAL IDENTIFIER – THE MEDICAL RESEARCH COUNCIL**

### **1. Trial identifier**

#### **1.1 Full title of trial**

RCT of CBT, graded exercise, and pacing versus usual medical care for the chronic fatigue syndrome

#### **1.2 Acronym**

PACE: Pacing, Activity, and Cognitive behaviour therapy; a randomised Evaluation

### **2. The need for a trial**

#### **2.1 What is the problem to be addressed?**

The chronic fatigue syndrome (CFS) is a condition characterised by chronic disabling fatigue and other symptoms, which is not associated with either an identifiable disease process or a major psychiatric illness.<sup>1-3</sup> Myalgic encephalomyelitis (ME) is thought by most to be synonymous with CFS.<sup>1-5</sup> The prevalence of CFS in primary care is between 1 and 2%.<sup>3</sup> An independent working party, reporting to the English Chief Medical Officer, recently concluded; “CFS/ME is a relatively common clinical condition, which can cause profound, often prolonged, illness and disability, and can have a substantial impact on the individual and the family.”<sup>4</sup> As many as half the patients are unemployed,<sup>6</sup> and they have 10 times the amount of sick-leave of other general medical outpatients.<sup>7</sup> The prognosis is poor; in primary care only a third improve by one year, and of those referred to secondary care less than 10% return to premorbid functioning.<sup>3,8</sup> The management of patients with CFS consumes significant resources in both primary and secondary care.<sup>2,3</sup> CFS patients use an annual average of 13 visits to their general practitioner and 5 visits to secondary care.<sup>6</sup> However there is now evidence that specific treatments can improve patient outcome. The CMO’s working party concluded;

“Therapeutic strategies that can enable improvement include graded exercise/activity programmes, cognitive behaviour therapy, and pacing.”<sup>4</sup> This positive statement was balanced in the report by, first the concern of patient organisations that graded exercise therapy (GET) and cognitive behaviour therapy (CBT) may worsen symptoms and disability, and second that pacing, although widely advocated by patients’ organisations, is as yet unsupported by scientific evidence.

#### **2.2 What are the principal research questions to be addressed?**

- (1) Are CBT and/or GET more effective than pacing in reducing both fatigue and disability?
- (2) Is pacing more effective than usual medical care?
- (3) Are there differential predictors of response to CBT and GET and does the mechanism of change differ?
- (4) Do different treatments have differential effects on outcomes (i.e. disability versus symptoms)?

- (5) What factors predict a favourable response to treatment in general and with specific treatments?
- (6) What are the mechanisms of change with successful treatment?
- (7) What are the relative cost-effectiveness and cost-utility of these treatments?

### 2.3 Why is a trial needed now?

*Efficacy:* Two independent systematic reviews have found that rehabilitative CBT and GET were the most promising treatments for CFS in secondary care.<sup>5,9,10,11</sup> Yet the authors criticised the methodology of the published trials for being too small, too selective, and using different outcome measures. No other treatments for CFS have been shown to be helpful in more than one RCT.<sup>5,11</sup> CBT is a more complex therapy than GET, requiring highly trained therapists, and is therefore less available through the NHS. In contrast to this evidence, 2,338 members of the patient charity *Action for ME (AfME)* reported that CBT and GET were more likely to make them worse rather than better.<sup>12</sup> Pacing and rest were reported to be more helpful.<sup>12</sup> Pacing has been described in the scientific literature as a lifestyle management that allows optimal adaptation to the illness, including an appropriate balance of rest and activity.<sup>4,13</sup> It has been advocated by exponents of the “envelope theory” of CFS, which states that a patient has a fixed and finite amount, or envelope, of energy that they must adapt to by managing activity.<sup>13</sup> A non-randomised comparison of adaptive (rather than rehabilitative) CBT, which included adaptive pacing therapy (APT) based on this model, found that, although fatigue improved, this treatment was no more effective than the control condition.<sup>14</sup> A recent systematic review concluded that there was insufficient evidence to recommend adaptive pacing at present.<sup>5,9,11</sup> There is therefore an urgent need to: (a) compare CBT and GET with both APT and usual medical care alone (UMC), seeking evidence of both benefit and harm (b) compare APT against UMC, and (c) compare CBT and GET to each other to clarify differential predictors and mechanisms of change.

*Differential outcomes:* Because CBT and GET are based on graded exposure to activity or exercise, they may preferentially improve disability, whilst APT, being based on the theory of staying within the limits of a finite amount of “energy”, may improve symptoms, but at the expense of disability. By measuring both symptoms and disability as our primary outcomes, we will be able to address this issue.

*Process of treatment:* We do not know the essential mechanism of successful rehabilitation from CFS. Do illness beliefs or focussing of attention on symptoms (symptom focusing) need to be changed by CBT? Or does CBT work solely by graded exposure to avoided activity, which also occurs with GET? Is increased physical fitness following increased physical activity, essential to recovery or not? How important is the alliance between therapist and patient? Is it important to adapt to the illness to allow symptomatic relief? A greater understanding of these processes will shed light on the nature of recovery from CFS and allow the development of more efficient treatments.

*Predictors of outcome:* We also need to know which patients require the more complex CBT rather than the simpler and more readily available GET. Previously found predictors of a negative outcome with treatment include mood disorder, membership of a self-help group, being in receipt of a disability pension, focusing on physical symptoms, and pervasive inactivity.<sup>3,15</sup> No predictive factor has been found in more than one published study, probably due to a type II error.

*Cost-effectiveness:* There are no published data on the cost-effectiveness of treatments for CFS. CBT is relatively expensive and uses scarce therapeutic resources: we need to know relative cost-effectiveness and cost-utility.

### 2.4 Systematic reviews

Two recent systematic reviews of treatments for CFS were published together, because their conclusions were the same.<sup>11</sup> Whiting and colleagues concluded that RCTs had shown that CBT and GET were “promising treatments”, with criticisms outlined in section 2.3. They found insufficient evidence to recommend adaptive pacing. The York University guidance, stemming from their review, recommended that a comparison of CBT, GET and pacing was particularly needed.<sup>5</sup>

## **2.5 How will the results of this trial be used?**

The results of this trial will: (a) allow health planners, clinicians and patients to choose treatment on the basis of both efficacy and cost; (b) provide evidence to either reassure or confirm patients’ doubts about the efficacy and negative effects of the more active rehabilitation therapies (CBT and GET) in contrast to adaptive pacing; (c) provide the first test of pacing against usual medical care; (d) indicate which patient characteristics predict response to which treatment; and (e) define the essential aspects of effective treatment as a step toward the development of more efficient therapies.

The trial will recruit from secondary care clinics run by three different disciplines (immunology, infectious disease and psychiatry) in six different centres in both England and Scotland to ensure sufficient heterogeneity to allow generalisation of the findings. We will not recruit directly from primary care because we wish to compare the efficacy of these treatments in patients whom GPs regard as requiring additional help and who are likely to have a worse prognosis (one of the recommendations CMO’s report<sup>4</sup>).

Furthermore, direct recruitment from primary care has been problematic in previous studies. Two recent trials of treatment for prolonged fatigue using large and well established primary care research networks recruited only 46 patients with CFS in three years in one study<sup>16</sup> and 44 patients in 2.5 years in the other (personal communication, Lucy Darbishire).

## **2.6 Risks to safety of the patients in the trial**

There is a discrepancy between patient organisation reports of the safety of CBT and GET and the published evidence of minimal risk from RCTs. A survey of AfME members suggested that GET can sometimes cause a set-back in symptoms or disability, rather than improvement.<sup>12</sup> AfME suggests that such set-backs probably results from rigidly applied GET that is not tailored to the patient’s disability. Our treatment manual by being based on mutually agreed and flexible programme that varies according to patient response. We will also carefully monitor for any adverse effects of the treatments, and will undertake a detailed assessment, at home if necessary, for any subject who drops out of treatment for this reason, following which they will be offered appropriate help.

## **3. The proposed trial**

### **3.1 The proposed trial**

This trial will compare the efficacy and adverse effects of four different treatments for CFS. All subjects will receive usual medical care (UMC), and in three arms this will be supplemented by a specific therapy. Hence the four groups will be CBT and UMC, GET and UMC, APT and UMC, and UMC alone while on a waiting list for treatment. We will also (a) study the process and predictors of effective therapy and (b) compare the cost-effectiveness of each treatment condition.

### **3.2 What is the proposed trial design?**

A four arm, single blind, randomised controlled trial in consecutive referrals of patients who meet operationalised criteria for CFS, with follow-up for 12 months.

### 3.4 What are the planned trial interventions?

All patients will receive UMC. Those allocated to specific treatments will all also receive 14 sessions of that treatment (CBT, GET or APT) with equal therapist time (90 minutes in the first session, and 50 minutes thereafter) for each therapy. We have chosen 14 sessions on the basis of the positive trials of CBT and GET,<sup>15,17,20</sup> as well as extensive clinical experience. RCTs of the least effective CBT and GET used 6 and 8 sessions.<sup>20,21</sup> Although one study of a pragmatic rehabilitation found that only 4t sessions were helpful,<sup>22</sup> we believe that this result may have been related to the lack of a treatment as usual control group, and that more than four sessions are necessary to achieve change. All interventions will be based on manuals apart from UMC, where guidance will be given to treat patients as usual (see appendices).

CBT will be based on the illness model of fear avoidance, used in the three positive trials of CBT.<sup>15,17,18</sup> There are three essential elements: (a) Assessment of illness beliefs and coping strategies, (b) Structuring of daily rest, sleep and activity, with a graduated return to normal activity, (c) Challenging of unhelpful beliefs about symptoms and activity (see appendices 2 & 6).

GET will be based on the illness model of both deconditioning and exercise avoidance, used in the previous trials.<sup>19,20,22</sup> Therapy involves an assessment of physical capacity, negotiation of an individually designed home aerobic exercise programme with set target heart rates and times, and sessional feedback with mutual planning of the next fortnight's home exercise programme (see appendices 3 & 6).

APT will be based on the illness model that CFS is an undetermined organic disease, but that APT can improve quality of life without affecting the core disease. APT involves assessment of the link between activity and subsequent symptoms and disability, using a daily diary, with advice to plan and pace activity in order to avoid exacerbations. Strategies include developing awareness of early warning of exacerbations; limiting demands; regular planned rest and relaxation, and alternating of different sorts of activities. The aim is to achieve optimal adaptation to the illness.<sup>13</sup> A/ME have helped to design the APT manual and have endorsed this version of pacing, which is based on what is published and what patients and clinicians have reported as helpful (see appendices 4,6 & 11).

UMC (the control treatment) will include symptomatic pharmacotherapy (see appendix 5), with no specific advice regarding activity and rest management beyond that normally given by the clinician; there will be no specific therapist involvement. In particular there will be no diary monitoring with consequent advice. Subjects randomised to UMC will be placed on a waiting list for the therapy of their choice, to start after their last follow-up interview, in order to improve recruitment and ensure adequate care. The nature of UMC actually given by individual clinicians will be recorded (see appendix 5).

### 3.4 What are the proposed practical arrangements for allocating participants to trial groups?

The Clinical Trial Unit (CTU) trial statistician will prepare subject numbers for each centre by permuted block randomisation, using a computerised randomisation system, so that equal allocation is achieved every N subjects recruited in each centre. N will be unknown to trial centres and will vary throughout the trial to prevent allocation predictions. Local centre doctors (including centre leaders) will assess consecutive clinic new patients, as usual, and pass on details of willing potentially eligible patients to the centre research nurse (RN) for trial screening. Reasons for non-participation at this stage, and demographic details, will be recorded. Once an eligible subject has given informed consent, and completed the baseline assessment by the centre RN, the RN will contact the centre leader, who will contact the CTU

web-site for an automatically given trial identification number and treatment allocation, with the trial co-ordinator (TC) being automatically informed at the same time. The centre leader will immediately inform the subject of his/her treatment group in person or by phone, and also inform the appropriate therapist or clinician (for UMC). We will not stratify our sample by anything beyond centres since there is no replicated evidence that any factor influences treatment response (section 2.3; predictors of outcome) and stratification by all possible factors would be elaborate and reduce recruitment. Potential predictors are common enough to be well distributed by chance alone in the 600 subjects to be studied.

### **3.5 What are the proposed methods for protecting against other biases?**

*Assessment bias* at outcome will be minimised by use of self-rated primary outcomes. The secondary measures include an exercise test and we will therefore endeavour to keep the outcome assessor conducting these (Research nurse: RN) blind to treatment group.

*Bias by non-participation* will be measured by recording measures from potential subjects who did not meet criteria for the trial and from those who refuse consent. Therapists will receive training and some supervision together in order to minimise inter-centre differences.

*Therapist compliance with treatments* will be monitored in two ways. (1) All therapists will receive weekly local supervision and monthly central group supervision. All therapy sessions will be audiotaped. Some tapes will be used by trainers/supervisors to provide feedback to therapists on competence and treatment fidelity. Any significant deviations from the manual will be noted. (2) One taped session per subject will be randomly chosen and assessed blindly and independently by two assessors to assess adherence to manual defined therapy.

*Subject non-compliance with treatment* will be measured both by recording attendance and by therapist ratings of adherence to therapy using a visual analogue scale.

*Generalisability* will be measured by comparing between different centres and disciplines.

### **3.6 What are the planned inclusion/exclusion criteria?**

*Inclusion criteria:* Subjects will be required to meet operationalised Oxford criteria for CFS.<sup>2</sup> This means 6 months or more of medically unexplained, severe, disabling fatigue affecting physical and mental functions.<sup>2</sup> We will operationalise CFS in terms of fatigue severity and disability as follows: a Chalder fatigue score<sup>23</sup> of four or more and an SF36 physical function score<sup>24</sup> of less than 75 (see section 3.9). We chose these broad criteria in order to enhance generalisability and recruitment. The more narrowly defined CDC criteria are about to be revised and then superseded by an empirically derived definition (PDW is a member of this CDC led group). Those subjects who also meet the criteria for “fibromyalgia” (chronic widespread pain) will be identified but included,<sup>25</sup> because CFS and “fibromyalgia” commonly coexist.<sup>26</sup> Subjects will be of either gender. There will be no upper age limit, but all subjects will be aged at least 18 years old, since younger patients usually require a different family oriented approach.<sup>27</sup> Subjects will be discouraged from starting over the counter medicines or alternative treatments, but if they do, they will be encouraged to report their use to the centre research nurse, so that their use can be compared between centres and treatment groups.

*Exclusion criteria:* The RN will use a standardised psychiatric interview,<sup>28</sup> under supervision by the centre psychiatrist, to exclude those who are at significant risk of self-harm and those with a chronic somatisation disorder, as well as determine the psychiatric exclusions listed in the Oxford diagnostic criteria for CFS.<sup>2</sup> All potential subjects will be screened for important medical exclusions, by history and physical examination.<sup>1,2,4</sup> Appropriate investigations<sup>4</sup> will be undertaken by either the referring doctor or the centre consultants (checked by the RN). Other exclusions will be: subjects who do not speak or read English adequately (because of the self-report questionnaires); subjects unable to either attend hospital reliably or to do

therapies; those less than 18 years old (see inclusions); those who have previously been treated within a fatigue clinic with CBT, GET or APT.

### **3.7 What is the proposed duration of treatment period?**

All subjects will have their first 4 sessions once weekly, and will then be seen fortnightly for 10 further sessions, making 14 sessions in total over 23 weeks. Clinical experience suggests that this initially intense therapy works best. The same amount of time spent with the therapist will control for non-specific therapeutic effects.

### **3.8 What is the proposed frequency and duration of follow up?**

Subjects will be seen at 10 weeks (between the 7<sup>th</sup> and 8<sup>th</sup> treatment sessions), 24 and 52 weeks after treatment starts.

### **3.9 What are the proposed outcome measures?**

#### Primary efficacy measures:

Since we are interested in changes in both symptoms and disability we have chosen to make both fatigue and physical function primary outcomes. This is because it is possible that a specific treatment may relieve symptoms without reducing disability, or vice versa. Both these measures will be self-rated. The 11 item Chalder fatigue questionnaire measures the severity of symptomatic fatigue,<sup>23</sup> and has been the most frequently used measure of fatigue in most previous trials of these interventions. We will use the 0,0,1,1 item scores to allow a categorical threshold measure of “abnormal” fatigue with a score of 4 having been previously shown to indicate abnormal fatigue.<sup>23</sup> A Likert scoring (0,1,2,3) will also be used, as a secondary outcome measure, to better measure response to treatment. The SF-36 physical function sub-scale<sup>24</sup> measures physical function, and has often been used as an important outcome measure in trials of CBT and GET. We will count a score of 75 (out of a maximum of 100) or more as indicating normal function, this score being one standard deviation below the mean score (90) for the UK working age population.<sup>29</sup>

#### Secondary measures:

*Efficacy:* 1. The self-rated Clinical Global Impression (CGI) change score (range 1-7) provides a self-rated global measure of change, and has been used in previous trials.<sup>30</sup> 2. Daytime physical movement (an objective measure of activity) will be measured over 48 hours with an Actiwatch attached to the ankle. 3. The Hospital Anxiety and Depression scale will measure change in anxiety and depression.<sup>31</sup> 4. The 36 item short-form health survey (SF-36) measures not only physical but also social and role functioning.<sup>24</sup> 5. The EuroQOL (EQ-5D) visual analogue scale provides a simple global measure of quality of life.<sup>32</sup> 6. The Client Service Receipt Inventory (CSRI), adapted for use in CFS,<sup>33</sup> will measure hours of employment/study, wages and benefits received, allowing another more objective measure of function. 7. An operationalised Likert scale (from much better to much worse) of the nine CDC symptoms of CFS.<sup>1</sup>

*Adverse effects:* Apart from finding out why subjects who prematurely stop their therapy did so (see section 2.6), we will also administer the CGI, the SF-36 physical functional scale and the operationalised nine CDC symptoms of CFS1 at all interviews, in order to monitor for significant set-backs.

*Possibly predictive variables (measured at baseline):* 1. The Queen’s College three minute step test (which measures heart rate response to exercise and estimates VO2max).<sup>34</sup> 2. Body mass index, which has been shown to predict poor functional response to GET.<sup>35</sup> 3. Pervasive inactivity (measured by actigraphy) has predicted poor response to CBT.<sup>15</sup> 4. Hospital Anxiety and Depression sub-scale scores for depression and anxiety have been shown to

predict poor outcome with treatment.<sup>36</sup> 5. Current membership of a self-help group, shown to predict poor outcome with CBT.<sup>36</sup> 5. The CSRI will measure disability benefits received,<sup>33</sup> again shown to predict poor outcome with CBT.<sup>15,36</sup> 6. We will ask subjects their preferential treatment. 7. We will also examine whether CDC or “ME” criteria define response, because of many patients and some clinicians believe that pacing is better than CBT and GET in these patients.<sup>1,4</sup>

*Process variables (measured during therapy and at follow-up):* Changes in fitness,<sup>34</sup> physical activity (by actigraphy), the belief that exercise/activity is harmful, the belief that symptoms indicate harm, the belief that control of activity is beneficial, and an enhanced sense of control of the illness will all be measured. We will also measure the strength of the therapeutic alliance.<sup>37</sup>

*Economic:* The number of hours per week of voluntary and paid work or study will be calculated. Service utilisation and costs of treatment will be calculated. The CSRI will collect service utilisation data, wages and benefits received.

### **3.10 How will the outcomes be measured at follow-up?**

All subjects will be re-assessed in clinic. Self-rated measures will be posted to the subject prior to the visit and checked for completion by the RN. Although all our primary and secondary outcomes are either self-rated or objective, we will endeavour to keep the RNs blind to treatment group in order to minimise interview bias. Subjects who drop out of treatment will be assessed as soon as possible, rather than waiting for the normal follow-up. Those who cannot attend clinic will be offered home assessments (or failing this assessment by telephone or by post). Those subjects who have dropped out of the study will be telephoned to offer an opportunity to learn why, and will be sent questionnaires by post for the two primary outcomes, if willing to receive them.

### **3.11 Will health service research issues be measured at follow-up?**

We will be measuring health and other service utilisation for all subjects, and the associated costs (best national estimates of long-run marginal opportunity costs). Lost productivity and caregiver costs will also be measured.

### **3.12 What is the proposed sample size and what is the justification for the assumptions underlying the power calculations?**

*Assumptions:* At one year we assume that 60% will improve with CBT, 50% with GET, 25% with APT and 10% with UMC. The existing evidence suggests that at one year follow up, 50 to 63% of subjects with CFS had a positive outcome, by intention to treat, in the three RCTs of rehabilitative CBT,<sup>15,17,18</sup> with 69% improved after an educational rehabilitation that closely resembled CBT.<sup>22</sup> This compares to 18 to 63% improved in the two RCTs of GET,<sup>19,20</sup> and 47% improvement in a clinical audit of GET.<sup>38</sup> For usual medical care 6% to 17% improved by one year in two RCTs.<sup>15,22</sup> There are no previous RCTs of APT to guide us,” but we estimate that APT will be at least as effective as the control treatments of relaxation and flexibility used in previous RCTs, with 26% to 27% improved on primary outcomes.<sup>18,19</sup> We propose that a clinically important difference would be between 2 and 3 times the improvement rate of UMC.

*Power analyses:* Our planned intention to treat analyses will compare APT against UMC, and both CBT and GET against APT. Assuming  $\alpha = 5\%$  and a power of 90%, we require a minimum of 135 subjects in the UMC and APT groups, 80 subjects in the GET group and 40 in the CBT group.<sup>39</sup> However these last two numbers are insufficient to study predictors, process, or cost-effectiveness. We will not be able to get a precise estimate of the difference between CBT and GET, though our estimates will be useful in planning future trials. As an example, to detect a difference in response rates of 50% and 60%, with 90% power, would

require 520 subject per group; numbers beyond a realistic two-arm trial. Therefore, we will study equal numbers of 135 subjects in each of the four arms, which gives us greater than 90% power to study differences in efficacy between APT and both CBT and GET. We will adjust our numbers for dropouts, at the same time as designing the trial and its management to minimise dropouts. Dropout rates were 12 and 33% in the two studies of GET and 3,10, and 40% in the three studies of rehabilitative CBT.<sup>12,14</sup> On the basis of our own previous trials, we estimate a dropout rate of 10%. We therefore require approximately 150 subjects in each treatment group, or 600 subjects in all. Calculation of the sample size required to detect economic differences between treatment groups requires data of cost per change in outcome, which is not currently available. Since costs are not expected to vary significantly between or within groups, the treatment determined number of 150 per arm is likely to find significant differences in cost-effectiveness.

### **3.13 What is the planned recruitment rate?**

All centres will recruit at a rate of a minimum of 33 subjects per year. All centres see a minimum of 100 new patients with undiagnosed chronic fatigue per year. We estimate that 50 patients will meet eligibility criteria, and a conservative estimate is that two thirds will agree to enter the trial. Only seven and 15% of eligible subjects refused to participate in the previous GET trials<sup>15,16</sup> and three, 10 and 26% of those eligible refused CBT.<sup>12,14</sup> We are therefore confident that recruitment, at an overall rate of 200 subjects per year is feasible and will achieve 600 participants over three years. We will however closely monitor recruitment, especially in the first six months, and the trial management committee, after advice from the TSC, will consider replacing those centres that either do not recruit sufficient subjects, or fail to provide quality data.

### **3.14 Are there likely to be any problems with compliance?**

Non-compliance was less than 10% in our own 3 RCTs, although higher in others trials. Since our estimates of efficacy were based on all these studies, which incorporated non-compliance, our numbers of subjects should be adequate, especially as non-compliance will not differentially affect predictors and process.

Compliance with both the treatments and the study will be maximized by the collaboration and support of *AfME*, and by the inclusion of APT, which is recommended by most patient charities, in the trial. The acceptability of and compliance with the UMC will be maximized by being placed on a waiting list for the therapy of their choice.

### **3.15 What is the likely rate of loss to follow-up?**

We estimate 10% on the basis of data summarized in section 3.12. We will contact lost subjects to gather as much outcome data as possible, particularly the two primary outcome measures, which could be recovered by phone, fax, or post.

### **3.16 How many centres will be involved? Six**

### **3.17 Are there any planned subgroup analyses?**

Not beyond the inter-centre comparisons of the two primary outcomes.

### **3.18 What are the proposed type of analyses**

*Efficacy:* We will analyse all outcomes by intention to treat. We will perform pair-wise comparisons of the proportions with a positive primary outcome in the APT and UMC groups, and in the APT and combined GET and CBT groups, using chi-squared tests. We will perform chi-squared tests for trend across the UMC, APT and GET groups, and across the

UMC, APT and CBT groups. Any inter-centre or baseline significant inter-group differences will be controlled for using logistic regression. Secondary end-points for efficacy will compare changes from baseline to 12 months on both the 33-point Chalder fatigue scale and 100-point SF36 physical function scores using analysis of covariance. Other secondary outcome measures will be compared by t tests or Kruskal Wallis tests, depending on the distribution.

*Adverse effects:* The drop-out rates and the prevalence of both specific and any adverse effects will be compared by Chi square test.

*Predictions and process of treatment:* Associations between post-treatment outcomes and both predictor and process variables (including demographic, illness duration, and other putative clinical indicators) will be examined using multiple linear and logistic regression modelling techniques, including a limited examination of first order interactions. We anticipate that the sample size will be sufficient to identify important general predictors from a random-split, training set of two thirds ( $\approx 400$ ), with partial validation in the remainder, used as a test set. Shrinkage techniques (to allow for over-optimism in variable selection) will be applied in the development of a prognostic model to be applied to patients outside the trial. Economic evaluations: The incremental cost-effectiveness/utility ratios will be derived and confidence intervals reported. Considering the difficulties of a ratio measure and the common finding of non-normality in the distribution of the criterion variable, we will employ bootstrapping methods. Cost-effectiveness acceptability curves will be fitted and net benefits calculated. Sensitivity analyses will also be carried out.

### **3.19 What is the proposed frequency of analyses?**

We will do one post-trial analysis, because we are interested in process, predictors and cost-effectiveness, which will require the full number of subjects. The Data Monitoring and Ethics committee may wish to collate blind adverse outcome data during the trial to ensure that no specific therapy is causing undue adverse effects.

### **3.20 Has any pilot study been carried out using this design?**

We ourselves completed three out of seven of the RCTs of CBT and GET. The therapies and measures to be used are essentially the same as used in these successful trials. Because APT is less well tested, we will pilot this treatment in the first six months of the trial.

### **3.21 Will there be NHS cost implications for this trial?**

Yes; the costs of the extra therapists and the service support costs.

### **3.21 Over what period is funding requested? Five years**

## **4. Trial management**

### **4.1 What are the arrangements for day to day management of the trial?**

The trial will be run by the trial co-ordinator who will be based at Barts and the London , with the principal investigator (PI), and alongside two of the six clinical centres. He/she will liaise regularly with staff at the Clinical Trials Unit (CTU) who themselves will be primarily responsible for randomisation and database design and management (overseen by the centre statistician Dr Tony Johnson), directed by Professor Simon Wessely, in collaboration with Professor Janet Darbyshire at the MRC CTU.

The six centre leaders, and co-leaders where appropriate, will oversee recruitment, inform subjects and therapist of their randomisation, and will help screen subjects. They will also be responsible for recruitment, training, and day-to-day supervision of the local therapists, centre

RN and database/clerical officer. The PI (PW) will chair the trial management committee (TMC, composed of applicants, collaborators, and TC), which will initially meet every 2 months for the first year and then as necessary.

#### **4.2 What will be the responsibilities of the applicants?**

Drs. Peter White (PW), Michael Sharpe (MS) and Trudie Chalder (TC) will be centre leaders. PW will be the co-trainer and co-supervisor of GET (with Ms Lucy Darbishire) and will supervise the trial coordinator. MS and TC will oversee training and supervision of CBT (with Mr Vincent Deary). TC will oversee training and co-supervise APT (with Dr Diane Cox). PW, MS, and TC will oversee treatment adherence.

#### **4.4 What will be the responsibilities of the staff employed on the grant?**

The *Trial co-ordinator* (TrCo) will be responsible for checking the quality of the central trial database, and will send local research nurses (RNs) query forms as necessary. The TrCo will monitor trial recruitment against targets and regularly communicate these data to centre leaders and the PL. Along with the applicants, he/she will train and help to supervise the local centre RNs and database/clerical officers. The TrCo will write a regular trial newsletter for subjects and trial staff. The TrCo will service the meetings of the TMC, TSC and DMEC. He/she will be primarily responsible for analysis and writing up, with appropriate support.

The local centre 0.6 WTE *Research Nurses* (RNs) will screen all potential and participating subjects, consenting the eligible subjects, and execute baseline and outcome assessments, endeavouring to remain blind to trial arm, providing preliminary summary analyses of actigraphy data analysed locally. They will send birthday and Christmas (or New Year) cards to all their centre subjects for the duration of the project.

The local centre 0.5 WTE *database entry clerical officer* will enter the hard copy data on the CTU designed database at a local level, sending the data regularly and electronically to the CTU. They will also be responsible for communication by phone and letter with potential and actual trial subjects, with an ansaphone available out of hours.

The three 0.5 WTE *therapists* at each centre, funded by the NHS, will receive training in both London and their centres in the first 6 months, then treat the subjects locally, monitor their subjects' treatment adherence and attendance, audiotaping every session, and attend the appropriate London centres monthly for supervision. In order to encourage manual adherence and treatment enthusiasm, the therapies will be provided by separate staff (CBT by a CB therapist, GET by a physiotherapist, and APT by an occupational therapist). Ms Lucy Darbishire (GKT), Dr Diane Cox (St Martin's College, Lancaster) and Mr Vincent Deary (South London and the Maudsley Trust) will help to train and supervise GET, APT and CBT respectively, on a part-time basis. Dr Paul McCrone (GKT) will analyse the health economic data.

#### **4.4 What will be the responsibilities of the named collaborators?**

Prof. Anthony Pinching will lead the Baits immunology centre. Dr David Wilks will co-lead the Edinburgh centre. Prof. Tim Peto and Dr Eleanor Feldman will co-lead the Oxford centre. Dr Gabrielle Murphy will lead the Royal Free centre. Professors Peto and Pinching and Dr Wilks will advise regarding any uncertain medical exclusions. Prof. Simon Wessely will oversee the CTU, with the support of Dr Tony Johnson and Prof. Janet Darbyshire. Prof. Martin Knapp will oversee the analysis of the health economic data. Prof. Tom Meade (London School of Hygiene and Tropical Medicine) is a senior consultant. Mr. Chris Clark, CEO of A/ME, will be a member of the TMC and help with external relations.

#### **4.5 Who will be the trial statistician?**

TBA (CTU post about to be appointed) will be supervised by Dr Tony Johnson.

#### 4.6 Trial Steering committee

*Chairman:* Professor Tom Craig, (GKT). *Independent members:* Professor Anne Farmer (Institute of Psychiatry); Dr Meirion Llewelyn (University of Wales); Mrs. Frankie Campling (ex-sufferer and CFS counsellor). *Applicants:* PW, MS and TC, and the trial co-ordinator.

### 5 Financial details of the trial

#### 5.1 Financial summary

*The total cost to the MRC is: £1,921,883*

*Research staff costs:* One London based trial co-ordinator (grade AR4) for 5 years: £234,258. Two non-London (Oxford & Edinburgh) based 0.6 WTE RNs (grade G) for 4.25 years: £164,440. Two non-London based 0.5 WTE database entry/clerical officers (CG5) 4.25 years: £102,186. Two London (RFH & GKT) based 0.6 WTE RNs (grade G) for 4.25 years: £183,302. Two London based 0.5 WTE database entry/clerical officers (CG5) for 4.25 years: £114,568. One London (two Barts/London centres) based WTE RN (grade G) for 4.25 years: £152,753. One London based WTE database entry/clerical officer (CG5) for 4.25 years: £120,729. One London based economist: 165 days over 5 years: £21,869. **Total: £1,097,266**

*Overheads:* 46 per cent of research salaries: Total: **£504,742**

*Equipment:* 12 “Actiwatch Plus” activity sensors (Cambridge Neurotechnology), 6 “Sleepwatch” analysis packages, 6 reader/interface base stations, 11 computers, printers and software, 36 Polar heart rate monitors and transmitter belts, 6 digital metronomes, twelve-inch steps and stop-watches for fitness testing, 18 audio machines, 3,150 audiotapes. **Total: £36,360**

*Staff Travel:* Inter alia: Travel and/or accommodation (5 nights maximum) expenses of therapists and research staff for training and/or supervision, centre leaders for TMC meetings. **Total: £64,880**

*Consumables:* Inter alia: CTU randomisation and database design and maintenance (78 days @ £385): £30,030. Therapist training/supervision consultancy: £45,240. Travel expenses for treatment of subjects: £10 per session for 450 subjects (14 visits): £63,000. Research travel expenses for subjects (£20 x 4 x 600): £48,000. A/ME consultancy costs: £4,312 (14 days).

**Total: £218,635**

*Costs to the NHS: £1,179,909*

*Costs of therapists:* We have approached our NHS providers for these costs. We need 7 WTE therapists in the 6 centres: 2.5 WTE of CBT, 2 WTE physiotherapists, and 2.5 WTE OTs. Considering different costs in and out of London, this amounts to £241,424 p.a. over 4.5 years (including 6 months training), a total of £1,086,359. Service costs amount to £93,550. **Total: £1,179,909.**

Year	2003/4	2004/5	2005/6	2006/7	2007/8	Total
Research	398,205	415,622	423,268	429,429	255,359	1,921,883
Treatment	241,424	241,424	241,424	241,424	120,663	1,086,359
Service	24,600	19,700	19,700	19,700	9,850	93,550
TOTAL	664,229	676,746	684,392	690,553	385,872	3,101,792

#### 5.2 Justification for support requested

*The trial coordinator* will be an experienced post-doctorate science graduate with research, administrative, statistical and computer experience. This experience is necessary for the multiple tasks required.

*The six 0.6 WTE local research nurses (RNs)* need to be trained in the use of the assessments and trial research methodology, and be able to use a computer in order to summarise actigraphy data. We have chosen nurses in order to be able to adopt a consistent and caring approach to subjects through the trial, helping to reduce dropouts, especially in the UMC arm. Each RN will complete 400 assessments in total, 100 a year, on top of screening other potential subjects. The initial assessment and consenting will take 3 hours, the later ones taking 1.5 hours. Face-to-face interviews are necessary for the SCDD and fitness/activity measures. Some assessments will be done at a subject's home.

*The six 0.5 WTE local data entry/clerical officers* will code and enter the trial data onto the CTU designed database at a local level, sending the data to the CTU by email. They will be responsible for keeping hard copies of data and consent forms, as well as being a contact point for staff and subjects.

*NHS funded therapists* need to be appropriately trained and experienced in treating patients independently as well as under supervision. When not treating trial patients they may be treating non-participants and will be required after the trial to provide treatments for the UMC group. Because of the relatively small number of subjects, they will be employed half time on the trial.

*Equipment & Consumables:* All research staff need computers for analysis and communication. We have previously found that travel expenses for subjects significantly enhances recruitment. Double expenses for research interviews allow subjects to return the Actiwatches. Co-training with specific therapists will enhance the quality of therapy. CTU expenses will enhance the quality of the data.

*Travel:* Centre leaders will attend the TMC every 2 months and then less often for 5 years. Therapists and their supervisors will attend London for 10 days initial training and then monthly supervision; to ensure optimal manual based therapy.

*Economics:* 165 days will be required over 5 years for training RNs and analysis.

## **6 Application History**

**6.1** A similar application of a much smaller two arm trial (FATIMA; Grant number G9825745) was submitted in full to the MRC in 1999, rated Alpha B, but not funded. The outline proposal of this study (G010039) was approved for a full proposal in October 2001. The major innovations in this application include close collaboration with *Action for ME*, two new arms (APT and UMC), a much larger number of subjects and centres, and the involvement of a clinical trial unit.

**6.2** We submitted a similar trial to the Department of Social Security (now Work and Pensions) in 2000, and agreement in principle to fund was given, although final funding was not forth-coming.

## **Appendices**

1. Participating centres. 2. CBT manual. 3. GET manual. 4. APT manual. 5. UMC guidance. 6. Manual explaining the essential elements of the therapies and how they are differentiated. 7. Knowledge of other current CFS trials. 8. Names and addresses of proposed members of the TSC. 9. Names and addresses of proposed members of the DMEC. 10. Proposed patient information sheet. 11. Letter of support from *AfME*. 12. Letters of agreement to be applicants or collaborators (lodged with MRC). 13. Letters confirming NHS provider support for the project (lodged with MRC).

1. Fukuda K et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. *Ann Intern Med* 1994; 121: 953-959.
2. Sharpe MC, et al. A report – chronic fatigue syndrome. *JR Soc Med* 1991; 84: 118-121.
3. Wessely SC et al. *Chronic fatigue and its syndromes*. Oxford, Oxford University Press, 1998.
4. Working group report to the Chief Medical officer, [www.doh.gov.uk/cmo/cfsmereport](http://www.doh.gov.uk/cmo/cfsmereport) 2002.
5. NHS Centre for Reviews and Dissemination. Interventions for the management of CFS/ME. *Effective Health Care* 2002; 7(4): 1-12.
6. Lloyd A & Pender H. The economic impact of chronic fatigue syndrome. *Med J Australia* 1992; 157: 599-601.
7. Twemlow SW et al. Patterns of utilization of medical care and perceptions of the relationship between doctor and patient with chronic illness including chronic fatigue syndrome. *Psychological Reports* 1997; 80: 643-58.
8. Joyce J et al. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. *Q J Med* 1997; 90: 223-33.
9. Bagnall AM et al. A systematic review of interventions for the treatment and management of chronic fatigue syndrome and/or myalgic encephalomyelitis. [www.vork.ac.uk/inst/crd/cfs.htm](http://www.vork.ac.uk/inst/crd/cfs.htm) 2001.
10. Mulrow CD et al. Defining and managing chronic fatigue syndrome. Rockville, MD, Agency for Health Care Policy, 02-E001, 2001.
11. Whiting P et al. Interventions for the treatment and management of chronic fatigue syndrome. *JAMA* 2001; 286: 1360-8.
12. Action for ME. A survey of members of Action for ME. 2001, Action for ME, London.
13. Pesek JR et al. An empirical investigation of the envelope theory. *JHum Behav Soc Env* 2000; 3: 59-77.
14. Friedberg F & Krupp LB. A comparison of cognitive behavioral therapy for chronic fatigue syndrome and primary depression. *Clin Infect Dis* 1994; 18 Suppl: 105-10.
15. Priiis JB et al. Cognitive behaviour therapy for chronic fatigue syndrome. *Lancet* 2001; 357: 841-7.
16. Ridsdale L et al. Chronic fatigue in general practice: is counselling as good as cognitive behaviour therapy? A UK randomised trial. *Br J Gen Pract* 2001; 51: 19-24.
17. Sharpe M et al. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomised controlled trial. *5M/1996*; 312: 22-26.
18. Deale A et al. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. *Am J Psychiatry* 1997; 154: 408-414.
19. Fulcher KY & White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. *BMJ* 1997; 314: 1647-52.
20. Wearden A et al. A randomised, double-blind, placebo controlled treatment trial of fluoxetine and a graded exercise programme for chronic fatigue syndrome. *Br J Psychiatry* 1998; 172: 485-90.
21. Lloyd A et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: A double-blind, placebo-controlled trial. *Am J Med* 1993; 94: 197-203.
22. Powell P et al. Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome. *5M/2001*; 322: 387-92.
23. Chalder T et al. Development of a fatigue scale. *JPsychosom Res* 1993; 37: 147-53.
24. Ware JE, Sherbourne C. The MOS 36-item short form health survey (SF36). *Med Care* 1992; 30: 473-83.
25. Wolfe F et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. *Arthr Rheum* 1990; 33: 160-72.
26. Jason LA et al. Chronic fatigue syndrome: comorbidity with fibromyalgia and psychiatric illness. *Med Psychiatry* 2001; 4: 29-34.
27. Chalder T et al. Family focused cognitive behaviour therapy for chronic fatigue syndrome in adolescents. *Arch Dis Child* 2002; 86: 95-7.
28. First MB et al. Structured Clinical Interview for DSM-IV Axis I disorders: Research Version (SCID-I/P). New York, Biometrics Research, 1996.
29. Jenkinson C et al. Short form 36 (SF-36) Health Survey questionnaire: normative data from a large random sample of working age adults. *BMJ* 1993; 306: 1437-40.
30. Guy W. *ECDEU Assessment Manual for Psychopharmacology*. Rockville, MD, NMH, 1976, 218-22.
31. Zigmond A & Snaith R. The hospital anxiety and depression scale. *Act Psychiatr Scand* 1983; 87: 361-70.
32. Brooks et al. EuroQol: the current state of play. *Health Policy* 1996; 37: 53-72.
33. Beecham JK & Knapp MRJ. Costing mental health interventions. In: Thornicroft G, *Measuring Mental Health Needs*. London, Gaskell, 2001.

34. McArdle WD et al. Reliability and interrelationships between maximal oxygen intake, physical work capacity and step test scores in college women. *MedSci Sports* 1972; 4: 182-6.
35. Fulcher KY & White PD. Strength and physiological response to exercise in patients with the chronic fatigue syndrome. *JNeurol Neurosurg Psychiatry* 2000; 69: 302-7.
36. Bentall RP. Predictors of response to treatment for chronic fatigue syndrome. *Br J Psychiatry* (in press).
37. Godfrey E et al. The development of a measure of psychotherapy process in primary care, (submitted).
38. White PD & Naish VAB. Graded exercise therapy for chronic fatigue syndrome: An audit. *Physiotherapy* 2001; 87: 285-8.
39. Machin D et al. *Sample size tables for clinical studies*. 2<sup>nd</sup> Ed, Oxford, Blackwell Sci Ltd, 1997.

- ends -